Enfermedades de la hemostasia primaria. Púrpuras vasculares. Enfermedades de las plaquetas

  1. Moretó Quintana, A.
  2. Sierra Aisa, C.
  3. Iruin Irulegui, G.
  4. Martín Martitegui, X.
  5. García-Ruiz, J.C.
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2016

Serie: 12

Número: 22

Pages: 1267-1274

Type: Article

DOI: 10.1016/J.MED.2016.10.020 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Objectifs de Développement Durable

Résumé

AbstractIntroduction Hemostasis is the process of blood clot formation when a vessel injury occurs. Primary hemostasis is involved with the formation of the primary platelet plug that serves to plug off small injuries, especially in microvessels in mucosal tissues (respiratory, gastrointestinal, genitorurinary tracts) or skin. This process is mediated by vascular spasm and platelets. Symtoms Clinical presentation is mainly mucocutaneous bleeding. Diagnosis A focused history and physical examination, as well as routine laboratory tests are the basis of the diagnosis when a bleeding disorder is suspected. If a congenital disease is suspected, genetic studies can provide an accurate diagnosis. Treatment In the case of vascular purpura, often the only available treatment is symptomatic. Treatment of platelet disorders varies widely depending on the etiology.

Références bibliographiques

  • Enjolras O, Wassef M, Mazoyer E, Frieden IJ, Rieu PN, Drouet L, et al. Infants with Kasabach-Merritt syndrome do not have “true” hemangio-mas. J Pediatr. 1997;130(4):631-40.
  • Gruman A, Liang MG, Mulliken JB, Fishman SJ, Burrows PE, Ko-zakewich HP, et al. Kaposiformhemagioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol. 2005;52(4):616-22.
  • Rodríguez V, Lee A, Witman PM, Anderson PA. Kasabach-Merritt phe-nomenon: case series and retrospective review of the mayo clinic expe-rience. J Pediatr Hematol Oncol. 2009;31(7):522-6.
  • Ryan C, Price V, John P, Mahant S, Baruchel S, Branda L, et al. Kasabach-Merritt phenomenon: a single centre experience. Eur J Haematol. 2010; 84(2):97-104.
  • Janic D, Brasanac D, Krstovski N, Dokmanovic L, Lazic J, Krsti Z. The use of recombinant activated factor VII during major surgery in a child with Kasabach-Merritt syndrome. Paediatr Anaesth. 2009;19(2):177-9.
  • Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telan-giectasia. N Engl J Med. 1995;333(14):918-922.
  • Ellaway C. Paediatric Fabry disease.Transl Pediatr. 2016;5(1):37-42.
  • Fernandes NF, Schwartz RA. A “hyperextensive” review of Ehlers-Dan-lossyndrome. Cutis. 2008;82(4):242-8.
  • Von Kodolitsch Y, De Backer J, Schüler H, Bannas P, Behzadi C, Bern-hardt AM, et al. Perspectives on the revised Ghent criteria for the diag-nosis of Marfan syndrome. Appl Clin Genet. 2015;16(8):137-55.
  • Castellano JM, Silvay G, Castillo JG. Marfan syndrome: clinical, surgical an anesthetic considerations. Semin Cardiothorac Vasc Anesth. 2013;18: 260-271.
  • Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health. 2013;49:995-1003.
  • Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kit-chen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135:603-33.
  • Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Sub-committees Working Group.ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063-5.
  • Ballmaier M, Germeshausen M. Advances in the understanding of congeni-tal amegakaryocytic thrombocytopenia. Br J Haematol. 2009;146(1):3-16.
  • Fiedler J, Strauss G, Wannack M, Schwiebert S, Seidel K, Henning K, et al. Two patterns of thrombopoietin signaling suggest no coupling bet-ween platelet production and thrombopoietin reactivity in thrombocyto-penia absent radii syndrome. Haematologica. 2012;97(1):73-81.
  • Kee Y, D’Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012;122(11):3799-806.
  • Chen Z, Shivdasani A. Regulation of platelet biogenesis: insight from the May-Hegglin anomaly and other MYH9-related disorders. J Thromb Haemost. 2009;7Suppl1:272-6.
  • Rao AK. Inherited platelet function disorders: overview and di-sorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am. 2013;27(3):585-611.
  • Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders. Haemophilia. 2012;18(4):154-60.
  • Liang HP, Morel-Kopp MC, Curtin J, Wilson M, Hewson J, Chen W, et al. Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients. Thromb Haemost. 2007;98(6):1298-308.
  • Israels SJ, El-Ekiaby M, Quiroga T, Mezzanos D. Inherited disor-ders of platelet function and challenges to diagnosis of mucocuta-neous bleeding. Haemophilia. 2010;16Suppl5:152-9.
  • Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a compre-hensive review. Ann N Y Acad Sci. 2013;128:26-43.
  • Shattil SJ, Bennett JS, McDonough M, Turnbull J. Carbenicillin and Pe-nicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest. 1980;65(2):329-37.
  • Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000-7.
  • Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci. 1998;316(2):94.
  • Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998;66(6):2145-52.
  • Álvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, et al. Observationversus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205-10.
  • Pamphilon DH, Aparicio SR, Roberts BE, Menys VC, Tate G, Davies JA. The myelodysplastic syndromes–a study of haemostatic function and pla-telet ultrastructure. Scand J Haematol. 1984;33(5):486-91.
  • Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in para-proteinemias and amyloidosis. SeminThromb Hemost. 2007;33(4): 339-49.
  • Gresele P. Diagnosis of inherited platelet function disorders: guidance from the SSC to the ISTH. J Thromb Haemost. 13(2):314-22.
  • Di Michele DM, Hathaway WE. Use of DDAVP in inherited and acqui-red platelet dysfunction. Am J Hematol. 1990;33(1):39-45.
  • Kosch A, Kehrel B, Nowak-Göttl U, Häberle J, Jürgens H. Thrombocyti-calpha-delta-storage-pool-disease: shortening of bleeding time after infu-sion of 1-desamino-8-D-arginine vasopressin. Klin Padiatr. 1999;211(4): 198-200.
  • Mannucci PM, Vicente V, Vianello L, Cattaneo M, Alberca I, Coccato MP, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986;67(4): 1148-53.
  • Livio M, Mannucci PM, Viganò G, Mingardi G, Lombardi R, Mecca G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986;315(12):731-5.
  • Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haema-tol. 2003;121(3):477-81.
  • Konkle BA. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program. 2011:391-6.
La source de données: Dialnet